They say it is all from this one over-the-counter treatment you can get almost anywhere

———-

Using this age-old remedy — reduces fatty liver disease?

Fatty liver disease is a growing problem worldwide.

People with type II diabetes or obesity have a high risk of developing fat deposits in the liver.

These fat deposits can cause scar-like damage to the organ.

The initial stages of fatty liver disease are relatively harmless.

But progression of fatty liver disease can lead to severe problems including cancer and death.

A recent study has indicated that aspirin could significantly lower the risks of developing advanced fatty liver disease.

This human research was carried out at Harvard Medical School in Boston. The results were published in Clinical Gastroenterology and Hepatology.

Everyone in the study was diagnosed with early-stage fatty liver disease — called non-alcoholic fatty liver disease.

At the start of the study, some people were taking aspirin and some people were not.

All the participants were assessed every 3 to 12 months to see if their fatty liver disease had progressed.

The study recruited 361 people and followed them for nine years.

“We performed a study of 361 adults with biopsy-confirmed non-alcoholic fatty liver disease, from 2006 through 2015.”

The scientists tracked numerous markers of fatty liver disease progression. They also monitored the aspirin usage of all the participants.

“Information collected at baseline and at each examination included frequency and duration of aspirin use.”

A little less than half of the participants used aspirin regularly.

“At enrollment, 151 subjects used aspirin daily.”

They then calculated the risk of advancement in fatty liver disease relative to aspirin use.

“We estimated the association of aspirin use with prevalent steatohepatitis (NASH) and fibrosis.”

Fatty liver disease triggers a buildup of fibrous protein which damages the liver — a process doctors call fibrosis.

When liver fibrosis proceeds to the next stage is called steatohepatitis (NASH).

Aspirin users were less likely to progress from non-alcoholic fatty liver disease to steatohepatitis (NASH).

The risk of developing a more advanced form of liver disease was decreased by 32 to 46%.

“Daily aspirin use was associated with significantly lower odds of NASH (adjusted odds ratio, 0.68) and fibrosis (adjusted odds ratio, 0.54).”

Scarring of the liver, caused by increased fibrosis, was also much less likely with regular aspirin use.

Advanced liver fibrosis was 37% less frequent in aspirin users.

“Daily aspirin users had significantly lower risk for developing incident advanced fibrosis vs non-regular users (adjusted hazard ratio, 0.63.)”

The analysis showed that people who used aspirin for a longer time period were more likely to have significant risk reduction.

Using aspirin for four or more years halved the risk of advancing fatty liver disease.

“This relationship was duration dependent, with the greatest benefit found with at least 4 years or more of aspirin use (adjusted hazard ratio, 0.50.)”

The research shows that aspirin may provide significant protection to people diagnosed with fatty liver disease.

“Daily aspirin use was associated with less severe features of NAFLD and NASH, and lower risk for progression to advanced fibrosis with time.”

Fatty liver disease is estimated to affect up to 25% of the population.

But it affects 80% of obese people — and one-third of those who go on to develop more aggressive forms of the disease.

Weight-loss through diet and exercise is the usual medical recommendation for the treatment of early stage non-alcoholic fatty liver disease.

Aspirin can be added to a small number of treatments and supplements which may lower the risks associated with increasing liver fat.

These include vitamin E and taurine.

You should always consult a healthcare practitioner about treating and diagnosing health-related problems.

———-